First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)
Options
BORIS DOI
Publisher DOI
PubMed ID
21527587
Description
Oral temozolomide has shown similar efficacy to dacarbazine in phase III trials with median progression-free survival (PFS) of 2.1 months. Bevacizumab has an inhibitory effect on the proliferation of melanoma and sprouting endothelial cells. We evaluated the addition of bevacizumab to temozolomide to improve efficacy in stage IV melanoma.
Date of Publication
2012
Publication Type
Article
Language(s)
en
Contributor(s)
von Moos, R | |
Seifert, B | |
Simcock, M | |
Goldinger, S M | |
Gillessen, S | |
Michielin, O | |
Cathomas, R | |
Schläppi, M | |
Moch, H | |
Schraml, P H | |
Mjhic-Probst, D | |
Mamot, C | |
Schönewolf, N | |
Dummer, R | |
Swiss Group for Clinical Cancer Research, (SAKK) |
Additional Credits
Series
Annals of oncology
Publisher
Oxford University Press
ISSN
0923-7534
Access(Rights)
open.access